Effect of oral capsule– vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 20, 2017, Pages 1985-1993

  Kao, Dina ^a   Roach, Brandi ^a   Silva, Marisela ^b   Beck, Paul ^b   Rioux, Kevin ^c   Kaplan, Gilaad G ^b   Chang, Hsiu Ju ^a   Coward, Stephanie ^d   Goodman, Karen J ^a   Xu, Huiping ^e   Madsen, Karen ^a   Mason, Andrew ^a   Wong, Gane Ka Shu ^a,f   Jovel, Juan ^a   Patterson, Jordan ^a   Louie, Thomas ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF VICTORIA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e INDIANA UNIVERSITY   (United States)

^f BGI SHENZHEN   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE;

ADVERSE OUTCOME; ARTICLE; ATRIAL FIBRILLATION; BACTEREMIA; CANADA; CAPSULE COLONOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; COMMUNITY STRUCTURE; CONFUSION; CONGESTIVE HEART FAILURE; FECAL MICROBIOTA TRANSPLANTATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE ENDOSCOPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MICROBIAL COMMUNITY; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RECURRENT INFECTION; SHORT FORM 36; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT RESPONSE; ADULT; AGED; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; FECES; FEMALE; MALE; MICROBIOLOGY; MICROCAPSULE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CAPSULES; CLOSTRIDIUM INFECTIONS; COLONOSCOPY; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; SECONDARY PREVENTION; YOUNG ADULT;

EID: 85037042631     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.17077     Document Type: Article

References (27)

1. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039-2046.
2. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-431.
3. Wilcox MH, Gerding DN, Poxton IR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017; 376(4):305-317.
4. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4): 500-508.
5. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693-702.
6. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5): 407-415.
7. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9): 609-616.
8. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772-1778.
9. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142-149.
10. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012;46(2):145-149.
11. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med. 2012;172(2):191-193.
12. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection. 2012;40(6):643-648.
13. Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med. 2017;167(1):34-39.
14. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-498.
15. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014;15(3):R46.
16. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149(1):223-237.
17. Garborg K, Waagsbø B, Stallemo A, Matre J, Sundøy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis. 2010;42(11-12):857-861.
18. Negrón ME, Kaplan GG, Barkema HW, et al. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. Inflamm Bowel Dis. 2014;20(11):2046-2055.
19. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: a tool for visualizing high-throughput microbial community data. Gigascience. 2013;2(1):16.
20. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693-702.
21. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835-843.
22. Abujamel T, Cadnum JL, Jury LA, et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C difficile infection with oral vancomycin or metronidazole. PLoS One. 2013;8(10):e76269.
23. Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2402-2409.
24. Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14(10):1433-1438.
25. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11): 1515-1522.
26. Staley C, Hamilton MJ, Vaughn BP, et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017;112(6):940-947.
27. Dubberke ER, Lee C, Orenstein R, Khanna S, Hecht G, Fraiz J. Efficacy and safety of RBX2660 for the prevention of recurrent Clostridium difficile infection: results of the PUNCH CD 2 trial. Open Forum Infect Dis. 2016;3(suppl 1):1341. doi:10.1093/ofid/ofw172.1044